Kevin Charles Gorman
Chief Executive Officer at Neurocrine Biosciences Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Neurocrine Biosciences Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Xencor Inc. June 16, 202697.5%
-
Xencor Inc. June 12, 202599.4%
-
Xencor Inc. June 13, 202498.1%
-
Xencor Inc. June 14, 202397.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Neurocrine Biosciences Inc. | Grant or award | +14,343 | — | — |
| Sep 11, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −7,839 | $156.22 | $1,224,609 |
| Jun 16, 2026 | Xencor Inc. | Grant or award | +10,302 | — | — |
| Jun 15, 2026 | Xencor Inc. | Open-market sale | −7,527 | $12.31 | $92,657 |
| May 19, 2026 | Neurocrine Biosciences Inc. | Option exercise | +205,088 | $43.24 | $8,868,005 |
| May 19, 2026 | Neurocrine Biosciences Inc. | Open-market sale | −245,088 | $154.33 | $37,824,431 |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Option exercise | +5,604 | — | — |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −3,024 | $124.12 | $375,339 |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Option exercise | +5,377 | — | — |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −2,901 | $124.12 | $360,072 |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Grant or award | +63,724 | — | — |
| Feb 13, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −34,380 | $124.12 | $4,267,246 |
| Jan 31, 2026 | Neurocrine Biosciences Inc. | Option exercise | +5,142 | — | — |
| Jan 31, 2026 | Neurocrine Biosciences Inc. | Shares withheld for tax | −2,845 | $136.06 | $387,091 |
| Aug 7, 2025 | Neurocrine Biosciences Inc. | Option exercise | +106,322 | $35.99 | $3,826,529 |
Questions about Kevin Charles Gorman
What boards is Kevin Charles Gorman on?
Kevin Charles Gorman sits on the boards of Neurocrine Biosciences Inc. and Xencor Inc.
What company is Kevin Charles Gorman the CEO of?
Kevin Charles Gorman is Chief Executive Officer of Neurocrine Biosciences Inc.
How long has Kevin Charles Gorman served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.